Clinical Research Directory

* INCLUSION CRITERIA: * Adults \>= 21 years * Severe tricuspid valve regurgitation with intact tricuspid leaflets, due to annular dilation, leaflet tethering, etc. * NYHA class III or IV congestive heart failure (symptomatic tricuspid regurgitation) * Cardiac size suitable for available TRAIPTA study devices according to NHLBI Core Lab analysis of cardiac CTA indicating a TRAIPTA extracardiac perimeter of 25-40cm. * Concordance of the study central clinical eligibility committee * Consents to participate, in writing, and willing to comply with all study procedures for the duration of the study EXCLUSION CRITERIA: * Prior cardiac surgery, which may preclude pericardial access, or known pericardial adhesions * Prior coronary artery stent in the atrioventricular groove * Severe mitral valve regurgitation assessed by echo * Left ventricular systolic dysfunction, LVEF \< 0.30 * Right atrial pacemaker lead if it might preclude trans-atrial access for TRAIPTA * Eligible for commercially-available transcatheter tricuspid valve replacement * Eligible for commercially-available tricuspid edge-to-edge repair (TTEER). Recurrent or persistent symptomatic tricuspid regurgitation despite TTEER is not excluded. * Having transcatheter heart valve implants at risk of compression by TRAIPTA based on anatomic location on pre-procedure CT * Severe pulmonary artery hypertension, pulmonary artery systolic pressure \>=60 mm Hg * Severe baseline renal excretory dysfunction, eGFR\<30mL/min/1.73m\^2 unless on renal replacement therapy * Evidence of thrombus in left atrial appendage on baseline CTA * Known hypersensitivity to study device materials (for example, nickel) * Acute coronary syndrome, myocardial infarction, or percutaneous coronary intervention within 30 days * Requiring other structural heart intervention or coronary revascularization procedure in next 3 months * Pregnancy or intent to become pregnant prior to completion of all 12-month protocol follow-up procedures